Director and 10% Owner Sells $489K in Atara Biotherapeutics Stock
summarizeResume
The sale of common stock by James Huang, who serves as both a Director and a 10% owner, is a notable event for Atara Biotherapeutics. The transaction value of nearly $490,000 is substantial for a company of ATRA's size, indicating a significant reduction in insider exposure. Shares were sold at a weighted average price of $6.07 on January 12, 2026, which is notably higher than the current stock price of $4.58. Investors may interpret this as a move to lock in gains, potentially putting downward pressure on the stock.
check_boxEvenements cles
-
Insider Sale
James Huang, a Director and 10% owner, disposed of 80,554 shares of Atara Biotherapeutics common stock.
-
Significant Value
The sale amounted to $489,019, a substantial transaction for the company.
-
Transaction Price
Shares were sold at a weighted average price of $6.07 on January 12, 2026, compared to the current stock price of $4.58.
auto_awesomeAnalyse
The sale of common stock by James Huang, who serves as both a Director and a 10% owner, is a notable event for Atara Biotherapeutics. The transaction value of nearly $490,000 is substantial for a company of ATRA's size, indicating a significant reduction in insider exposure. Shares were sold at a weighted average price of $6.07 on January 12, 2026, which is notably higher than the current stock price of $4.58. Investors may interpret this as a move to lock in gains, potentially putting downward pressure on the stock.
Au moment de ce dépôt, ATRA s'échangeait à 4,58 $ sur NASDAQ dans le secteur Life Sciences, pour une capitalisation boursière d'environ 32,2 M $. La fourchette de cours sur 52 semaines allait de 4,25 $ à 19,15 $. Ce dépôt a été évalué avec un sentiment de marché négatif et un score d'importance de 8 sur 10.